KPV
Also known as Lys-Pro-Val, Alpha-MSH (11-13), Alpha-MSH C-terminal tripeptide
KPV is a three amino acid fragment of alpha-melanocyte stimulating hormone that carries the anti-inflammatory effect of the hormone without its pigmentation effect. It is used for inflammatory bowel symptoms, skin inflammation and general inflammation control.
Reviewed by the amino101 editorial team. , first published .
Quick start
What people commonly do. Not a prescription.- Typical dose
- 250 to 500 mcg (injectable or nasal); 500 mcg to 1 mg (oral)
- How often
- once or twice daily
- Where
- Oral capsule for gut complaints, taken away from food; subcutaneous in the belly for systemic use; topical cream for skin
- Timing
- oral doses on an empty stomach; injectable timing is flexible
- Effects timeline
- gut and skin inflammation 1 to 2 weeks, fuller effect 3 to 4 weeks
- Storage
- fridge 2 to 8 C once mixed, use within 4 weeks; oral capsules at room temperature
- Cycle length
- 4 to 8 weeks
- Break between
- 2 to 4 weeks, or use only during flares
Overview
KPV is the last three amino acids (lysine, proline, valine) of alpha-MSH, a hormone best known for triggering melanin production. Researchers noticed in the 1980s and 1990s that this small C-terminal fragment reproduced the anti-inflammatory activity of the full hormone while having essentially no effect on skin pigmentation. That separation made it attractive as a tool for studying inflammation and later as a candidate treatment for inflammatory conditions.
The strongest evidence is in mouse models of colitis. Oral KPV, and especially KPV packaged in nanoparticles to survive the gut, reduced inflammation, weight loss and tissue damage in chemically induced and genetically driven colitis models. It also reduced inflammation in mouse models of skin conditions, uveitis, arthritis and lung injury. In cell studies it blunts NF-kB activation, the master switch for inflammatory gene expression.
There are no published human trials of KPV as a standalone treatment. Its use for gut and skin complaints is based on the animal data plus the fact that alpha-MSH itself has been studied in humans. People report benefit for irritable bowel symptoms, eczema and post-infection inflammation, but these are anecdotes. Oral, nasal, topical and injectable forms all circulate, and there is no data on which route is best in humans.
How it works
KPV enters cells and interferes with NF-kB signaling, preventing the transcription factor from moving into the nucleus and switching on inflammatory genes. This reduces production of cytokines like TNF-alpha, IL-6 and IL-1 beta. Unlike the parent hormone, it does not seem to depend on the classic melanocortin receptors, and it is transported into intestinal epithelial cells by the PepT1 transporter, which is upregulated during inflammation. That transporter route explains why oral KPV can act directly on the inflamed gut lining. It also has direct antimicrobial activity against some bacteria and fungi, which may add to its effect on gut and skin.
Where the research stands
Intestinal inflammationModerate evidence
- Colitis and IBD-type inflammation. Oral KPV reduced inflammation, weight loss and tissue damage in several mouse colitis models; the best results used protective nanoparticle formulations that are not what most vendors sell.
- Gut barrier and PepT1 uptake. Cell and mouse studies show inflamed intestinal cells actively transport KPV inside, which is the rationale for oral dosing.
Skin inflammationEmerging
- Eczema and contact dermatitis. Mouse ear swelling and dermatitis models improved with KPV; human use of topical creams is anecdotal.
- Skin infections. In vitro activity against Staphylococcus aureus and Candida; no clinical data.
Systemic inflammation and immune conditionsWeak or mixed
- Arthritis, uveitis and lung injury. Single mouse studies for each; nothing in humans.
- rodentOral KPV reduced colitis severity, weight loss and inflammatory cytokines in mouse models of IBD.
- rodentKPV loaded nanoparticles delivered to the colon lowered inflammation at a fraction of the free peptide dose.
- in vitroBlocked NF-kB nuclear translocation and cytokine release in cultured intestinal and immune cells.
- rodentReduced skin inflammation and ear swelling in mouse models of contact dermatitis.
- in vitroShowed direct antimicrobial activity against Staphylococcus aureus and Candida albicans.
Rodent and in vitro mean no human data for that finding. Human pilot means small, often uncontrolled. Human RCT means randomized and controlled. Clinical means an approved drug with regulatory data.
Levels over time
Modeled from the half-life. Illustrative, not measured.A half-life of 30 min against dosing every 24 h means each dose has cleared before the next. Nothing stacks; you start from zero every time, and the tissue effect is what carries over.
The short half-life is why once or twice daily dosing is standard, and for gut use the peptide is meant to be taken up by inflamed intestinal cells on contact rather than to reach any particular blood level.
KPV dosage and protocols
Most people run 4 to 8 weeks and then stop to see whether symptoms return. For chronic gut or skin conditions a common pattern is to use it around flares rather than continuously, since there is no long term safety data of any kind.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Gut inflammation | 500 mcg to 1 mg | once or twice daily | Oral capsule, empty stomach |
| Gut or systemic, injectable | 250 to 500 mcg | once or twice daily | Subcutaneous, abdomen |
| Systemic, nasal | 250 to 500 mcg | once or twice daily | Intranasal |
| Skin inflammation | thin layer of low concentration cream | once or twice daily | Topical on affected skin |
Oral doses go on an empty stomach, 30 minutes or more before food, so the peptide is not competing with dietary protein for the same transporter. Injectable and nasal timing does not seem to matter. In gut stacks it is often taken at the same time as oral BPC-157.
Injectable and nasal protocols commonly report 250 to 500 mcg once or twice daily. Oral capsules are often 500 mcg to 1 mg. Topical creams are used for local skin inflammation.
Dose calculator
U-100 insulin syringeUnits are a volume on the syringe, not an amount of peptide. Concentration changes every time you change the water volume. The standalone calculator explains the math.
| Vial | Suggested water | Concentration | Low dose draw |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 10 units |
| 10 mg | 2 mL | 5 mg/mL | 5 units |
How to reconstitute KPV
- 1
Wash your hands and wipe the work surface. Swab both vial stoppers with alcohol and let them dry.
- 2
Pick the water volume with the calculator above and write it on the vial. The concentration means nothing without it.
- 3
Draw the bacteriostatic water into a mixing syringe.
- 4
Insert at an angle and let the water run down the inside wall. Never squirt it straight onto the powder.
- 5
Swirl gently or leave it to dissolve. Do not shake.
- 6
Label with the date and water volume. Store in the fridge at 2 to 8 C and use within about 4 weeks.
- 7
Unmixed vials keep for months in the fridge and longer in the freezer, sealed and out of light.
- Full walkthrough with syringe reading and site rotation: reconstitution guide.
- ✓White, fluffy cake
Lyophilized powder should look like a small white puck or fluffy cake at the bottom of the vial. That is a proper freeze-dry.
- ✓Clear after mixing
Once dissolved the solution should be water-clear with nothing floating in it.
- !Slight clumping
Small clumps that dissolve with gentle swirling are fine. Shipping compacts powder.
- ✕Collapsed or melted
Powder stuck to the sides, glassy, or shrunken means it got hot in transit. Contact the vendor.
- ✕Cloudy or particles
Persistent cloudiness or visible particles after mixing means degraded or contaminated product. Do not use it.
- Week 1 to 2
Users with gut complaints often report less bloating, urgency or discomfort in the first week or two; skin users report less itching and redness.
- Week 3 to 4
If it is going to help, the effect is usually clear by now; many people describe it as a steady reduction in background inflammation rather than a dramatic change.
- Week 5 to 8
Gains plateau; this is when most people stop and see whether symptoms come back, which is the only way to tell if it was the peptide.
Interactions and stacking
BPC-157synergistic
The standard gut pairing; KPV dampens inflammation in the lining while BPC-157 drives repair.
VIPcompatible
Both reduce inflammation by different routes and appear together in mold and gut protocols; no data on the combination.
Melanotan 2compatible
Both derive from alpha-MSH but KPV does not hit the pigment receptor, so there is no overlap in effect and no known interaction.
Immunosuppressants and biologicscaution
Adding another anti-inflammatory on top of drugs like TNF blockers has never been studied and could blunt immune responses further.
Antibiotics or antifungalscompatible
KPV has mild antimicrobial activity in vitro; no interaction, but it is not a substitute for treatment of an actual infection.
Active infectioncaution
Suppressing NF-kB signaling broadly could in theory weaken a needed immune response; most people pause it when they are sick.
Safety
- ▲Nausea, mostly with injectable use
- ▲Headache
- ▲Injection site irritation
- ▲Stomach upset from oral capsules in some people
- ▲Fatigue reported by a minority of users
- ▲No human clinical trials. All efficacy claims are from mice and cell culture.
- ▲Oral products vary widely in whether the peptide survives digestion; published mouse work used protective formulations.
- ▲Mild side effects reported anecdotally include nausea and headache, usually with injectable use.
- ▲Suppressing inflammation broadly could in theory blunt a needed immune response during an active infection.
- ▲Do not confuse it with melanotan; KPV does not cause tanning.
- ■Signs of infection appear or an existing infection gets worse
- ■Gut symptoms worsen rather than improve after two weeks
- ■Signs of an allergic reaction such as hives, swelling or trouble breathing
- ■You are starting an immunosuppressant or biologic and have not discussed it with the prescriber
Community poll
Self-reported by visitors. Not clinical evidence.KPV: frequently asked
Does KPV work orally?
In mice, yes, particularly when protected in nanoparticles so it reaches the colon intact. Plain oral capsules sold on the research market may lose some peptide to digestion. For gut complaints many people still start oral because the target tissue is the gut lining itself.
Will KPV make me tan like melanotan?
No. KPV is the fragment of alpha-MSH that does not bind the melanocortin 1 receptor responsible for pigmentation. It was studied specifically because it keeps the anti-inflammatory action without the tanning effect.
Is KPV useful for eczema or psoriasis?
Mouse skin inflammation models responded well, and topical alpha-MSH derived peptides have been studied for skin conditions. Human data on KPV specifically is lacking. People use topical creams at low concentration on affected areas and report mixed results.
Can I take KPV long term?
There is no long term safety data in humans. Most community protocols run it for four to eight weeks and then pause. For chronic conditions some people cycle it around flares rather than taking it continuously.
References
- Oral delivery of KPV nanoparticles alleviates ulcerative colitis in mice. Molecular Therapy, 2015
- Anti-inflammatory peptide KPV is transported by PepT1 into intestinal epithelial cells. Gastroenterology, 2008
- Alpha-MSH and its C-terminal tripeptide KPV: anti-inflammatory and antimicrobial activity (review). Peptides, 2006
- Antimicrobial activity of alpha-MSH and its tripeptide fragment KPV against S. aureus and C. albicans. Peptides, 2000